Racial disparities in refusal of stroke thrombolysis in Chicago

Neurology

Volumn 90, Issue 5, 2018, Pages e359-e364

  Mendelson, Scott J ^a   Aggarwal, Neelum T ^b   Richards, Christopher ^a   O'Neill, Kathleen ^c   Holl, Jane L ^a   Prabhakaran, Shyam ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c AMERICAN HEART ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; ARTICLE; BLACK PERSON; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; EMERGENCY WARD; FEMALE; HEALTH DISPARITY; HUMAN; ILLINOIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT REFUSAL; AGED; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; REGISTER; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CHICAGO; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 85049792020     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004905     Document Type: Article

References (40)

1. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With the Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2010;3:291-302.
2. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632-1640.
3. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasmin-ogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
4. Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With the Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013;6:543-549.
5. Aparicio HJ, Carr BG, Kasner SE, et al. Racial disparities in intravenous recombinant tissue plasminogen activator use persist at primary stroke centers. J Am Heart Assoc 2015;4:e001877.
6. Cruz-Flores S, Rabinstein A, Biller J, et al. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2091-2116.
7. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001;32:1061-1068.
8. Hsia AW, Edwards DF, Morgenstern LB, et al. Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study. Stroke 2011;42: 2217-2221.
9. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011;123:750-758.
10. Ekundayo OJ, Saver JL, Fonarow GC, et al. Patterns of emergency medical services use and its association with timely stroke treatment: findings from get with the guidelines-stroke. Circ Cardiovasc Qual Outcomes 2013;6:262-269.
11. Prabhakaran S, Khorzad R, Brown A, Nannicelli AP, Khare R, Holl JL. Academic-community hospital comparison of vulnerabilities in door-to-needle process for acute ischemic stroke. Circ Cardiovasc Qual Outcomes 2015;8:S148-S154.
12. Prabhakaran S, Lee J, O'Neill K. Regional learning collaboratives produce rapid and sustainable improvements in stroke thrombolysis times. Circ Cardiovasc Qual Outcomes 2016;9:585-592.
13. Decker C, Chhatriwalla E, Gialde E, et al. Patient-centered decision support in acute ischemic stroke: qualitative study of patients' and providers' perspectives. Circ Car-diovasc Qual Outcomes 2015;8:S109-S116.
14. Vahidy FS, Rahbar MH, Lal AP, Grotta JC, Savitz SI. Patient refusal of thrombolytic therapy for suspected acute ischemic stroke. Int J Stroke 2015;10:882-886.
15. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009;119:107-115.
16. QuintilesIMS and The American Heart Association I. Stroke patient management tool coding key [online]. Available at: osstatic.outcome.com/online-doc-qi/Stro-kePMT/crf/StrokeCodingKey.pdf. Accessed June 30, 2017.
17. Huang P, Khor GT, Chen CH, Lin RT, Liu CK. Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria. Acad Emerg Med 2011;18:273-278.
18. American Academy of Neurology policy on consent issues for the administration of IV tPA [online]. Available at: aan.com/uploadedFiles/Website-Library-Assets/Documents/6.Public-Policy/1.Stay-Informed/2.Position-Statements/3.PDFs-of-all- Position-Statements/IV.pdf. Accessed July 21, 2016.
19. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
20. Rosenbaum JR, Bravata DM, Concato J, Brass LM, Kim N, Fried TR. Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice. Stroke 2004;35:e353-e355.
21. Gong J, Zhang Y, Feng J, et al. How best to obtain consent to thrombolysis: individualized decision-making. Neurology 2016;86:1045-1052.
22. Kleindorfer D, Khoury J, Broderick JP, et al. Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. Stroke 2009;40:2502-2506.
23. Howard G, Prineas R, Moy C, et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Stroke 2006;37:1171-1178.
24. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015;132:873-898.
25. Brown AF, Liang LJ, Vassar SD, et al. Neighborhood disadvantage and ischemic stroke: the Cardiovascular Health Study (CHS). Stroke 2011;42:3363-3368.
26. Kawachi I, Colditz GA, Ascherio A, et al. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA. J Epidemiol Community Health 1996;50:245-251.
27. Lutfiyya MN, Lipsky MS, Bales RW, Cha I, McGrath C. Disparities in knowledge of heart attack and stroke symptoms among adult men: an analysis of behavioral risk factor surveillance survey data. J Natl Med Assoc 2008;100:1116-1124.
28. Fang MC, Panguluri P, Machtinger EL, Schillinger D. Language, literacy, and characterization of stroke among patients taking warfarin for stroke prevention: impli-cations for health communication. Patient Educ Couns 2009;75:403-410.
29. Smith SG, Wolf MS, von Wagner C. Socioeconomic status, statistical confidence, and patient-provider communication: an analysis of the Health Information National Trends Survey (HINTS 2007). J Health Commun 2010;15(suppl 3):169-185.
30. Cooper LA, Roter DL, Carson KA, et al. The associations of clinicians' implicit attitudes about race with medical visit communication and patient ratings of interpersonal care. Am J Public Health 2012;102:979-987.
31. Flickinger TE, Saha S, Roter D, et al. Respecting patients is associated with more patient-centered communication behaviors in clinical encounters. Patient Educ Couns 2016;99:250-255.
32. Schwei RJ, Kadunc K, Nguyen AL, Jacobs EA. Impact of sociodemographic factors and previous interactions with the health care system on institutional trust in three racial/ethnic groups. Patient Educ Couns 2014;96:333-338.
33. Gadhia J, Starkman S, Ovbiagele B, Ali L, Liebeskind D, Saver JL. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke 2010;41:300-306.
34. Choi HY, Kim EH, Yoo J, et al. Decision-making support using a standardized script and visual decision aid to reduce door-to-needle time in stroke. J Stroke 2016;18: 239-241.
35. McMeekin P, Flynn D, Ford GA, Rodgers H, Gray J, Thompson RG. Development of a decision analytic model to support decision making and risk communication about thrombolytic treatment. BMC Med Inform Decis Mak 2015;15:90.
36. Schwamm LH. Acute stroke: shifting from informed consent to informed refusal of intravenous tissue-type plasminogen activator. Circ Cardiovasc Qual Outcomes 2015; 8:S69-S72.
37. Addo J, Ayerbe L, Mohan KM, et al. Socioeconomic status and stroke: an updated review. Stroke 2012;43:1186-1191.
38. Kerr GD, Higgins P, Walters M, et al. Socioeconomic status and transient ischaemic attack/stroke: a prospective observational study. Cerebrovasc Dis 2011;31:130-137.
39. Arrich J, Mullner M, Lalouschek W, Greisenegger S, Crevenna R, Herkner H. Influence of socioeconomic status and gender on stroke treatment and diagnostics. Stroke 2008;39:2066-2072.
40. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association get with the guidelines-stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J 2012;163:392-398, 398.e1.